QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, May 15, 2003, 23(10):4127-4133

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (68) Citing Articles via Google Scholar Google Scholar Articles by Veldhuis, W. B. Articles by Marzo, V. D. Search for Related Content PubMed PubMed Citation Articles by Veldhuis, W. B. Articles by Marzo, V. D.

 Previous Article  |  Next Article 

Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil against In Vivo Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases

W. B. Veldhuis,^1,2 * M. van der Stelt,^3 * M. W. Wadman,³ G. van Zadelhoff,³ M. Maccarrone,⁴ F. Fezza,⁵ G. A. Veldink,³ J. F. G. Vliegenthart,³ P. R. Bär,² K. Nicolay,¹ and V. Di Marzo⁵

¹Department of Experimental In Vivo Nuclear Magnetic Resonance, Image Sciences Institute, ²Department of Experimental Neurology, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands, ³Department of Bio-Organic Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, 3584 CH, Utrecht, The Netherlands, ⁴Department of Biomedical Sciences, University of Teramo, 64100 Teramo, Italy, and ⁵Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, 80078 Pozzuoli, Naples, Italy

Type 1 vanilloid receptors (VR₁) have been identified recently in the brain, in which they serve as yet primarily undetermined purposes. The endocannabinoid anandamide (AEA) and some of its oxidative metabolites are ligands for VR₁, and AEA has been shown to afford protection against ouabain-induced in vivo excitotoxicity, in a manner that is only in part dependent on the type 1 cannabinoid (CB₁) receptor. In the present study, we assessed whether VR₁ is involved in neuroprotection by AEA and by arvanil, a hydrolysis-stable AEA analog that is a ligand for both VR₁ and CB₁. Furthermore, we assessed the putative involvement of lipoxygenase metabolites of AEA in conveying neuroprotection. Using HPLC and gas chromatography/mass spectroscopy, we demonstrated that rat brain and blood cells converted AEA into 12-hydroxy-N-arachidoylethanolamine (12-HAEA) and 15-hydroxy-N-arachidonoylethanolamine (15-HAEA) and that this conversion was blocked by addition of the lipoxygenase inhibitor nordihydroguaiaretic acid. Using magnetic resonance imaging we show the following: (1) pretreatment with the reduced 12-lipoxygenase metabolite of AEA, 12-HAEA, attenuated cytotoxic edema formation in a CB₁ receptor-independent manner in the acute phase after intracranial injection of the Na⁺/K⁺-ATPase inhibitor ouabain; (2) the reduced 15-lipoxygenase metabolite, 15-HAEA, enhanced the neuroprotective effect of AEA in the acute phase; (3) modulation of VR₁, as tested using arvanil, the VR₁ agonist capsaicin, and the antagonist capsazepine, leads to neuroprotective effects in this model, and arvanil is a potent neuroprotectant, acting at both CB₁ and VR₁; and (4) the in vivo neuroprotective effects of AEA are mediated by CB₁ but not by lipoxygenase metabolites or VR₁.

Key words: arvanil; anandamide; cannabinoid; vanilloid; CNS; excitotoxicity; ouabain; neuroprotection; neurodegeneration

---

Received Jan. 21, 2003; revised Mar. 6, 2003; accepted Mar. 6, 2003.

This article has been cited by other articles:

				M. L. Yates and E. L. Barker Inactivation and Biotransformation of the Endogenous Cannabinoids Anandamide and 2-Arachidonoylglycerol Mol. Pharmacol., July 1, 2009; 76(1): 11 - 17. [Abstract] [Full Text] [PDF]

				B. Zhong and D. H. Wang N-oleoyldopamine, a novel endogenous capsaicin-like lipid, protects the heart against ischemia-reperfusion injury via activation of TRPV1 Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H728 - H735. [Abstract] [Full Text] [PDF]

				J. Chemin, J. Nargeot, and P. Lory Chemical Determinants Involved in Anandamide-induced Inhibition of T-type Calcium Channels J. Biol. Chem., January 26, 2007; 282(4): 2314 - 2323. [Abstract] [Full Text] [PDF]

				B. Nilius, G. Owsianik, T. Voets, and J. A. Peters Transient Receptor Potential Cation Channels in Disease Physiol Rev, January 1, 2007; 87(1): 165 - 217. [Abstract] [Full Text] [PDF]

				S. R. Kim, S. U. Kim, U. Oh, and B. K. Jin Transient Receptor Potential Vanilloid Subtype 1 Mediates Microglial Cell Death In Vivo and In Vitro via Ca2+-Mediated Mitochondrial Damage and Cytochrome c Release J. Immunol., October 1, 2006; 177(7): 4322 - 4329. [Abstract] [Full Text] [PDF]

				A. Bilkei-Gorzo, I. Racz, O. Valverde, M. Otto, K. Michel, M. Sastre, and A. Zimmer Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors PNAS, October 25, 2005; 102(43): 15670 - 15675. [Abstract] [Full Text] [PDF]

				G. Appendino, L. De Petrocellis, M. Trevisani, A. Minassi, N. Daddario, A. S. Moriello, D. Gazzieri, A. Ligresti, B. Campi, G. Fontana, et al. Development of the First Ultra-Potent "Capsaicinoid" Agonist at Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channels and Its Therapeutic Potential J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 561 - 570. [Abstract] [Full Text] [PDF]

				S. R. Kim, D. Y. Lee, E. S. Chung, U. T. Oh, S. U. Kim, and B. K. Jin Transient Receptor Potential Vanilloid Subtype 1 Mediates Cell Death of Mesencephalic Dopaminergic Neurons In Vivo and In Vitro J. Neurosci., January 19, 2005; 25(3): 662 - 671. [Abstract] [Full Text] [PDF]

				G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, S. C. Azad, M. G. Cascio, S. O. Gutierrez, M. van der Stelt, et al. CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity Science, October 3, 2003; 302(5642): 84 - 88. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help